Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Calls for Maintenance or Expansion of R&D Tax Credit System at METI Hearings
August 6, 2012
- 61% of Clinics that Issue Legal Prescriptions Claim Premium for Generic-Name Prescribing: JMA Survey
August 3, 2012
- JMA to Draft COI GLs by End of Year
August 3, 2012
- JMA Executive Board Member Komori Calls For Efforts for “Joint Fight” by Municipalities to Slash IPV Price
July 30, 2012
- 4 Pharmaceutical Associations Issue Joint Statement Calling For Eradicating Online Illegal Drug Sales
July 27, 2012
- EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
- Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
- 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
- Wholesaler FTC to Make Serious Efforts for Improving “Services of Convenience”
July 13, 2012
- Japan Should Not Copy Foreign HTA Systems: Mr Grainger of PhRMA
July 12, 2012
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
- 60% of Respondents Are Unaware That Colorectal Cancer is Asymptomatic Ill: Survey
July 9, 2012
- OPIR Says Surplus of Drug Imports “Unrelated to International Competitiveness of Domestic Industry”
July 6, 2012
- JPMA Calls for Restoration of 30% Maximum Deduction Rate in R&D Tax Credit System
July 4, 2012
- 30% of Medical Institutions Introduce Generic Name Prescribing: Yakukeiren Survey
July 3, 2012
- JGA Begins Posting Information on Out-of-Stock Products, Delayed Shipments on Website
July 3, 2012
- JPA Vice President Miura Calls for Discussions on Role of Pharmacies; Raises Question about Dividends Paid by Listed Pharmacies
June 27, 2012
- Legal Prescription Receipt Rate at Record-High 64.6% in FY2011: JPA
June 26, 2012
- JPWA, NPhA Confirm Need for Thorough Efforts “at Ground Level” for Distribution Improvements
June 25, 2012
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…